Advanced lung cancer, breast cancer
Conditions
Interventions
experimental group:High Throughput Drug Sensitivity Assay/Next-generation Gene Sequencing
Sponsors
Anhui Provincial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Advanced breast cancer or lung cancer diagnosed by histopathology and / or cytology; 2. With malignant pleural effusion, diagnostic criteria: malignant cells are found in pleural effusion, pleural biopsy confirmed,exudative pleural effusion that can't explained by other reasons; 3. From the end of the last chemotherapy more than 4 weeks if ever received chemotherapy (including intrathoracic chemotherapy); 4. Age 18 to 75 years; 5. ECOG 0 ~ 2 points; 6. Survival is expected to = 3 months; 7. Hematologic examination within 1 week prior to randomization, meeting the following requirements (no transfusion and hematopoietic growth factor injection within 14 days before randomization): 1) WBC=3 ×10^9/L, ANC=1.5×10^9/L, Hb=80g/L, PLT=80×10^9/L; 2) TBIL =1.5×ULN (normal upper limit), ALT and AST =2×ULN (if liver metastasis, = 5×ULN; 3) Endogenous creatinine clearance =60 ml / min (Cockcroft-Gault formula); 8. Sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1. The expected survival <3 months; 2. Thoracic infection; 3. Chylothorax 4. pleural effusion package; 5. Patients with brain metastases (unless the researchers believe that the brain metastases are now controlled and stable, generally not recommended into the group); 6. with pulmonary embolism, superior vena cava compression syndrome and other cancer patients can not enter the emergency group; 7. Active haemorrhage in other areas (any severe bleeding grade 3 or more in CTCAE 4.0) occurring within the first 4 days of screening; 8. Imaging studies have shown that the tumor has been infiltrating the vital vessels or the researchers determined that the patient's tumor during the treatment of high blood vessels may be caused by the invasion of vital fatal bleeding situation; 9. In patients with abnormal coagulation, those with a bleeding tendency (14 days before randomization: INR within the normal range without the use of anticoagulants); use of anticoagulants or vitamin K antagonists such as warfarin, (1 mg orally once daily) or a small dose of aspirin for prophylactic purposes, with a prothrombin time international normalized ratio (INR) of 1.5 or less, or a small dose of aspirin Daily dosage not exceeding 100 mg); 10. Occurred within the year before the screening of venous thromboembolic events such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis (due to preoperative chemotherapy vein catheterization caused by venous thrombosis by the investigator to determine the recovered, ) And pulmonary embolism; 11. Pregnant or lactating women, as well as unwilling to take contraceptive measures of men and women; 12. The agreement can not be agreed and followed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of pleural effusion;Tumor size; | — |
Countries
China
Contacts
Public ContactYue-yin Pan
Anhui Provincial Hospita
Outcome results
None listed